A Potential Use of Dopamine Agonist and Monoamine Oxidase B Inhibitor in Parkinson’s Disease as Apply by Transdermal Patch.

Main Article Content

Shubhrajit Mantry
Suvarna Deshmukh
Kiran Mahajan
Shital Bidkar
Ganesh Dama


Parkinson's disease (PD) is an advancing neurological disorder. The characteristic physical symptoms, which also include dopaminergic neuron loss and Lewy pathology, include rigidity, postural instability, bradykinesia, and resting tremors. Clinical symptoms in the elderly worsen over time due to decreased neurotransmitter levels, protein homeostasis disruption, mitochondrial malfunction, and oxidative stress. Parkinson's disease (PD) pathogenesis is likewise reliant on protein misfolding. and malfunction of the ubiquitin-proteasome system. The main purpose of continuous drug administration in PD is to maintain continuous dopaminergic activation, provide higher drug concentrations, prolong benefits, and reduce side effects. For example, transdermal delivery of monoamine oxidase-B or dopamine agonists inhibitors the drug delivery method itself may have an impact on a drug's bioavailability, which may therefore have an impact on a drug's effectiveness and tolerability, as well as on patient compliance. Additionally, examine the pharmacological and pharmacokinetic characteristics of dopamine agonists and MAO-B inhibitors for the treatment of Parkinson's disease in both its early and advanced stages

Article Details

How to Cite
Shubhrajit Mantry, Suvarna Deshmukh, Kiran Mahajan, Shital Bidkar, & Ganesh Dama. (2023). A Potential Use of Dopamine Agonist and Monoamine Oxidase B Inhibitor in Parkinson’s Disease as Apply by Transdermal Patch. Journal of Coastal Life Medicine, 11(1), 2546–2557. Retrieved from https://www.jclmm.com/index.php/journal/article/view/716


Vicki Oldfield, Gillian M. Keating and Caroline M. Perry, Rasagiline A Review of its Use in the Management of Parkinson’s disease. Adis drug evaluation, Drugs 2007; 67 (12): 1725-1747

Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B. Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism & Related Disorders. 2013 Jan 1;19(1):37-42.

Wang Y, Yu X, Zhang P, Ma Y, Wang L, Xu H, Sui D. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease. Journal of Pharmacological Sciences. 2018 Sep 1; 138(1):31-7.

Gorukanti SR, Li L, Kim KH. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation. International journal of pharmaceutics. 1999 Dec 10;192(2):159-72.

Claudine M. Baldwin and Gillian M. Keating, Rotigotine Transdermal Patch A Review of its Use in the Management of Parkinson’s Disease, Adis drug evaluation, CNS Drugs 2007; 21 (12): 1039-1055.

Zhou W, Lv C, Zhang Q, Zong S, Wang M. Pharmacokinetics, pharmacodynamics, and safety of rasagiline transdermal patch: a preliminary study in healthy Chinese subjects. Clinical Drug Investigation. 2018 Feb;38(2):125-33.

Dhiman S, Singh TG, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. Int J Pharm Pharm Sci. 2011;3(5):26-34.

Senek M, Nyholm D. Continuous drug delivery in Parkinson’s disease. CNS drugs. 2014 Jan;28(1):19-27.

Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. British journal of pharmacology. 2015 May;172(9):2179-209.

Kanabar VB, Patel VP, Doshi SM. Formulation and evaluation of transdermal patch of Cefdinir with various polymers. The Pharma Innovation. 2015 Aug 1;4(6, Part B):74.

Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review. The pharma innovation. 2012 Jun 1;1(4, Part A):66. Available at www.thepharmajournal.com

Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA. Selegiline transdermal system: current awareness and promise. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007 Aug 15;31(6):1153-63.

Lane ME. Skin penetration enhancers. International journal of pharmaceutics. 2013 Apr 15;447(1-2):12-21.

Raza C, Anjum R. Parkinson's disease: Mechanisms, translational models and management strategies. Life sciences. 2019 Jun 1;226:77-90.

Ho DH, Je AR, Lee H, Son I, Kweon HS, Kim HG, Seol W. LRRK2 kinase activity induces mitochondrial fission in microglia via Drp1 and modulates neuroinflammation. Experimental Neurobiology. 2018 Jun;27(3):171.

Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003 Sep 11;39(6):889-909.

Andrew J Lees, John Hardy, Tamas Revesz, Parkinson’s disease, Lancet (British edition). 2009;373(9680):2055-66.

Hong R, Li X. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Med ChemComm. 2019;10(1):10-25.

Löhle M, Reichmann H. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC neurology. 2011 Dec;11(1):1-7.

Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Experimental neurology. 2004 Jun 1;187(2):455-9.

Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Journal of neural transmission. 2001 Sep;108(8):985-1009.

Binde CD, Tvete IF, Gasemyr JI, Natvig B, Klemp M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. European journal of clinical pharmacology. 2020 Dec;76(12):1731-43.

Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Leading article, Drugs & aging. 2001 Jun;18(6):389-96.

Oster S, Radad K, Scheller D, Hesse M, Balanzew W, Reichmann H, Gille G. Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. European journal of pharmacology. 2014 Feb 5;724:31-42.

Scheller D, Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M, Bezard E. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neuroscience letters. 2008 Feb 13;432(1):30-4.

Frampton JE. Rotigotine transdermal patch: a review in Parkinson’s disease. CNS drugs. 2019 Jul;33(7):707-18.

Wood M, Dubois V, Scheller D, Gillard M. Rotigotine is a potent agonist at dopamine D 1 receptors as well as at dopamine D 2 and D 3 receptors. British journal of pharmacology. 2015 Feb;172(4):1124-35.

Chahine LM, Stern MB. Rasagiline in Parkinson's disease. International Review of Neurobiology. 2011 Jan 1;100:151-68.

Gore S. A., 1 Satpute V. V., 1 Gholve S. B., 1 Bhusnure O. G., 2 Bhosale P. H., 3 Phutke P. B, A Systematic Review on Transdermal Patches, Int. J. Pharm. Sci. Rev. Res., 45(2), July - August 2017; Article No. 08, Pages: 36-47.

Tanwar H, Sachdeva R. Transdermal drug delivery system: A review. International journal of pharmaceutical sciences and research. 2016 Jun 1; 7(6):2274